Seattle Genetics has entered into an exclusive, worldwide collaboration agreement with Daiichi Sankyo for the development of antibody-drug conjugates (ADCs) targeting a single antigen found on multiple types of solid tumors.     Under the terms of the collaboration, Seattle Genetics will receive an upfront payment of $4 million, development milestones and royalties on worldwide sales of any ADC products. Daiichi Sankyo is responsible for research, product development, manufacturing and comm...